Should terminally ill patients have the right to try experimental drugs that haven't finished clinical trials?
When it’s a matter of life or death, time is a luxury many patients cannot afford. In the United States, 10-29% of adult patients don’t live during their stay in the Intensive Care Unit (ICU) (Critical Care Statistics, 2024), where medical teams give it their all against the cruelest of diseases. When standard medical treatments fail, terminally ill patients may either accept death or take experimental treatments that can be expensive, risky, and unpredictable.
So, should patients have the right to try experimental, non-FDA-approved therapies? On one hand, granting access allows patients to make decisions for their own bodies and health, offering them a chance to survive. On the other hand, skipping the intense steps of clinical trials introduces serious risks, including experimenting on unconscious patients, irreversible changes to health, and a heavy financial burden on families.
One frightening, yet reassuring, statistic is that over 90% of experimental drugs fail clinical trials due to toxicity or lack of efficacy (Sun et al., 2022). Clinical trials are important for protecting patients by ensuring clear and consistent data are obtained before a drug is legally allowed to enter the market. Furthermore, many terminally ill patients are typically ineligible for trials due to underlying conditions or organ dysfunction (FDA, 2020) that could distort trial results or put them in even more danger, leaving patients searching for alternative pathways.
Another problem to consider is that many patients in the ICU may be unconscious or unable to make decisions for themselves due to the severity of their condition. In this case, experimenting on a patient who cannot give informed consent poses a moral and ethical dilemma. While some may believe wanting to live is the obvious choice, a patient who survives experimental treatment may face severe paralysis, brain damage, or other serious side effects they would have chosen not to endure. For that reason, it is critical for patients to give consent, express their wishes, and delegate individuals who can make decisions on their behalf beforehand.
To address these issues and ensure patients get a fair chance to survive, two legal pathways exist in the United States. The first is the Right to Try Act, a federal law that allows terminally ill patients who have exhausted all other treatment options to request eligible experimental drugs directly from manufacturers while bypassing FDA and Institutional Review Board (IRB) approvals (FDA, 2024). The second pathway is the Expanded Access (Compassionate Use) by the FDA, which grants patients access to unapproved drugs with review from doctors, the drug manufacturer, and the Institutional Review Board (IRB) (FDA, 2022).
However, these two pathways are often brought into direct conflict regarding speed and accessibility. The Right to Try Act bypasses federal oversight and may be deemed essential, as dying patients cannot afford delays or wait in their care that review may cause. In reality, the FDA already authorizes most expanded access requests within a few hours (FDA, 2022). The true obstacle to patients receiving treatment quickly is getting drug manufacturers to agree, identically impacting both pathways as neither mandates manufacturers to supply a treatment. Moreover, both have a major financial limitation involving insurance. Even though patients are in dire need of medication now, insurance companies frequently refuse to pay for experimental treatments (Walker, 2019). Someone in a life-or-death situation should not have to worry about the financial burden or cost they will bring on themselves or their family if they do not end up surviving.
A remarkable real-world example of the impact of experimental therapy is fully explained by the memoir The Perfect Predator by Steffanie Strathdee and Tom Patterson. While traveling in Egypt, Tom contracted a lethal superbug named Acinetobacter baumannii. As Tom’s condition worsened, he was transferred from the hospital in Egypt to Germany and then San Diego, all by air. He underwent septic shock, which is extremely deadly, several times before slipping into a coma. Tom reached a point where his ICU medical team had exhausted every single treatment and FDA-approved antibiotic. Tom’s wife, Steffanie, an epidemiologist, used her scientific background, institutional status as a professor, and professional connections to use an experimental alternative. This alternative is phage therapy. Phages are specialized viruses that attack and kill bacteria, like the one threatening Tom’s life. Working day and night among her physician friends, researchers, and even the United States Navy, she received bacteriophage cocktails customized to Tom’s specific infection, and he received emergency phage therapy in 2016 through the Expanded Access pathway (Corbyn, 2019).
Tom’s case is a miracle and a brilliant example of all the complications and struggles of experimental care. Firstly, Tom was unconscious and unable to consent, sometimes believing he could live and other times saying to “pull the plug.” Tom survived, but it also highlights limitations in accessibility. Tom’s wife was an epidemiologist who could get proposals written quickly from every party involved. The average patient does not have these resources and would most likely succumb to their illness while trying to find suitable experimental options. Thankfully, though, due to Tom’s case under Expanded Access, all information was documented, with some of the data contributing to the launch of the Center for Innovative Phage Applications and Therapeutics (IPATH) at UC San Diego (Finder, 2022). This means if experimental treatments save one patient's life, they could lead to saving more lives and becoming more refined in the future.
In conclusion, terminally ill patients need the right to try experimental drugs to honor their choices over their own bodies and freedom when standard medications fail. However, unmonitored access without making patients fully aware of the risks, or offering such therapies to healthier patients, turns into exploitation, serious physical suffering, or even death. Healthcare policies must implement safeguards by requiring patients to explicitly state their wishes regarding experimental care and designate decision makers if they are in a situation where they cannot. Secondly, review by the IRB must remain so that trained individuals can protect vulnerable patients from unsafe or unjust experimentation. And lastly, patients and healthcare providers should be made more aware of pathways like Expanded Access so that life-saving treatment isn’t only for the financially able or privileged. All patients must have the same opportunities. By allowing patients to make their own decisions and further healthcare for all, we can get closer to saving more lives while upholding medical ethics and integrity.
Sources



